WO2000013679A1 - Arzneistoffhaltiges pflaster mit drei funktionalen schichten - Google Patents
Arzneistoffhaltiges pflaster mit drei funktionalen schichten Download PDFInfo
- Publication number
- WO2000013679A1 WO2000013679A1 PCT/EP1999/006346 EP9906346W WO0013679A1 WO 2000013679 A1 WO2000013679 A1 WO 2000013679A1 EP 9906346 W EP9906346 W EP 9906346W WO 0013679 A1 WO0013679 A1 WO 0013679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- plaster according
- medicament
- fibers
- containing plaster
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Definitions
- the invention relates to a plaster containing medicinal products for the delivery of active pharmaceutical ingredients and, if appropriate, further substances via the skin of the human body.
- TTS transdermal therapeutic systems
- Devices for delivering nitroglycerin for the therapy of angina pectoris, nicotine for giving up smoking, estradiol for treating postmenopausal complaints, clonidine for lowering blood pressure, for example, are commercially available. Numerous other drugs are also suitable for this form of therapy.
- TTS has a systemic effect on other organs of the body after the active substance has previously been absorbed by the bloodstream through the skin and distributed in the organism.
- a prerequisite for transdermal therapy is the sufficient permeability of the active ingredient through the skin, which is only sufficient with some active ingredients.
- water is also suitable as a well-tolerated substance for improving the permeation properties of the skin.
- a particularly advantageous possibility of using permeation promotion lies in devices which use the body's own water or moisture for this purpose. For example, people excrete about half a liter of water a day through so-called "perspiratio insensibilis", ie through diffusion of water vapor that does not involve sweating and is not perceived by the body. On the order of magnitude, this corresponds to a water loss of approx. 0.5 kg per 2 m 2 of body area and day and thus about 25 mg / cm 2 - ä.
- Medicinal plasters that contain vapor barriers that counteract this loss of water are referred to as "occlusive"; they generally have the desired increase in permeation for the active substance introduced. This is very often caused by metal foils or plastic foils which are slightly permeable to water vapor, e.g. made of polyethylene terephthalate.
- plasters which contain non-stretch films, damage the skin through shear effects or cuts in the edge area of the plasters. Since the skin itself is stretchable due to its structure, a plaster that is stretchable to a limited extent has far more favorable wearing properties than a plaster based on non-stretchable films. Furthermore, the extensibility of soft matrices largely prevents the adhesive from escaping from the side, since the shear effect on the adhesive matrix does not occur.
- US 4,753,231 describes a water vapor permeable, active ingredient-free plaster consisting of a mechanically flexible back layer, which is provided with an adhesive layer on the skin side and carries a wound pad on it.
- Multilayer systems are also known in which a paper, nonwoven fabric or textile fabric is introduced between a soft plastic film and the active substance-containing adhesive layer (JP 2 212 423). In this way, an improved positive contact between the backing layer and the matrix is to be achieved.
- the present invention is based on the object of advantageously combining the two desirable properties, occlusivity or partial occlusiveness and extensibility.
- a drug-containing plaster with a layered structure, consisting of a) a layer composed of fibers, b) a layer limiting the water transport on the basis of a thermoplastic polymer, and c) at least one matrix layer containing the active substance.
- the plaster can have a removable protective film.
- the stretchable layer constructed from the fibers can be made of a textile, e.g. woven or knitted surface material, or consist of a non-textile non-woven composite.
- the elasticity is sufficient, as is generally achieved by a geometrical arrangement of a fiber composite that is familiar to the person skilled in the art.
- an extensibility of at least 1% of the initial dimension in length or width will suffice.
- expansion of the extension length of at least 30 5s may be useful.
- the elastic recovery force of such fiber composites should not exceed 1 N / cm at 5% elongation.
- the dosage of topical plasters and transdermal therapeutic systems depends on the area applied and therefore, in the interest of a uniform and uniform dosage, the elasticity should generally also be limited. This can be achieved, for example, by the fact that the stretch restoring force at a stretch of 10% and more is clearly above 5 N / cm. In this way, possible overdosing due to overstretching during application can be largely avoided.
- the base material of the fibers should comply without limitation with the principles of toxicological suitability for use on the skin.
- largely inert base polymers such as polyethylene, polypropylene, polyester, e.g. PET, preferably, but also viscose, cotton, wool or silk can correspond to the purpose according to the invention.
- the binding of the fibers to one another is basically arbitrary. If a mechanical-textile connection is not available or not sufficient, additional bonding and strengthening of the materials can be achieved with the help of physical or chemical processes.
- thermoplastic binders can be mentioned by way of example, e.g. according to US 4,003,783.
- the layer limiting the water transport between the fiber-containing layer and the adhesive matrix consists of a thermoplastic polymer. Polymer layers that limit or at least influence the water transport from the skin to the outside are suitable for this.
- the layer is not necessarily a monolithic photo lie, since the occlusivity can also be limited by porosity.
- polymers polyvinyl chloride, polyethylene, polyurethanes, polypropylene, diene / polystyrene copolymers, polymethacrylates, polyisoprene, polyesters, for example polyethylene terephthalate, polyvinyl acetate, polyvinyl alcohol, cellulose and its derivatives, polyamides and copolymers of the abovementioned plastics, this list is only exemplary.
- Resins in particular rosin esters or hydrocarbon resins, and plasticizers customary in polymer technology can be used to match the thermoplastic properties of these materials.
- the structure of the thermoplastic layer can entail that the active ingredient can diffuse into the layer containing the thermoplastic polymer shortly after production from the drug-carrying layers.
- the active ingredient can also be added preventively to the thermoplastic polymer layer, which can result in advantageous additional reservoir properties.
- the layer thickness of the thermoplastic film provided it is formed with a uniformly thick layer, can be, for example, between 5 and 500 ⁇ m.
- a function according to the invention can be expected with an additional dependence on the polymer properties. Depending on the density of the polymers and additives used, this corresponds to an application weight of approx. 10 to 100 g / m 2 .
- protective substances such as pigments, antioxidants, metal chelators or the like can be added to the polymer layer.
- pigments antioxidants, metal chelators or the like
- thermoplastic polymer A self-resetting effect of the polymer layer may be desirable, but is in no way a prerequisite for the function according to the invention.
- the application of thermoplastic polymer will be so small that the mechanical limitation of the stretch comes from the fiber-containing layer.
- Essential to the invention is only the control of the water vapor access through the thermoplastic polymer layer, which enables the overall composite to control the water vapor release under physiological conditions in the range from approximately 10 to 600 g / m 2 -d, preferably approximately 50 to 300 g / m 2 - d allowed. Experimentally, these values correspond to temptation conditions of 90% relative air humidity against 30% relative air humidity at 40 ° C.
- thermoplastic polymer layer has an impregnating effect on the fiber-containing cover layer and thus mechanical immigration of the layer, which is softer as a rule, is avoided. It is particularly important that the thermoplastic layer and the third, drug-carrying layer are bonded directly. This can be achieved by choosing the base materials of the polymer layer and the active substance-containing layers.
- the principle according to the invention can be used both in matrix systems and in reservoir / membrane systems, which are to be regarded as the third, active substance-containing layer of the patch according to the invention.
- the manufacture of such systems is possible in a number of ways:
- a TTS matrix produced according to known technology which is located on a film which has been provided with a adhesive layer as a later release liner, can be laminated on with a thermoplastic film and then covered with a textile or fleece-like fibrous layer using heat and / or pressure get connected.
- the adhesive bond is often improved by flowing around the fiber texture with melting thermoplastic polymer mass.
- the punching knife can stop in front of the release liner film and provide the central positioning of a TTS on the protective film for later easier application to the skin.
- the base material of the thermoplastic polymer layer is applied by melt flow extrusion from the melt, by layer application from a solvent-containing polymer solution, or by an equivalent method to a non-adhesive auxiliary film and then the fiber-containing layer is laminated onto the free surface.
- Heat and / or pressure can be used to improve the bond.
- the fiber-containing layer can advantageously be applied in the wet state and dried together with the thermoplastic polymer layer in combination. This process produces a particularly strong bond, which is regularly accompanied by a flow around the fiber texture with melting or temporarily dissolved thermoplastic polymer mass.
- the composite of fiber-containing layer and thermoplastic polymer is laminated directly onto the matrix or matrix composite layer, which on the other side is already equipped with a release-coated release liner.
- a desired geometric shape such as a circle, rounded rectangle, etc.
- thermoplastic polymer layer can also be laminated as a film directly onto the fiber-containing layer, if necessary under heat and / or pressure.
- the composite of fiber-containing layer and thermoplastic polymer is then laminated directly onto the matrix (or matrix composite) layer produced according to the rules known to the person skilled in the art, which layer is already equipped on the opposite side with the release-coated release liner. Die cutting and packaging can then be carried out according to the above rules.
- FIG. 1 a plaster according to the invention with a single layer
- FIG. 2 a plaster according to the invention with two layers
- FIG. 3 a plaster according to the invention with two layers
- Matrix and central drug reservoir 4: a plaster according to the invention with overlapping anchoring between the fiber-guiding layer and the thermoplastic polymer layer,
- FIG. 5 shows a detailed drawing of a plaster according to the invention with an overlapping anchoring between the fiber-guiding layer and the thermoplastic polymer layer.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99968625A EP1107742A1 (de) | 1998-09-03 | 1999-08-28 | Arzneistoffhaltiges pflaster mit drei funktionalen schichten |
BR9913609-0A BR9913609A (pt) | 1998-09-03 | 1999-08-28 | Emplastro para medicamentos |
KR1020017002469A KR20010073008A (ko) | 1998-09-03 | 1999-08-28 | 3개의 기능 층을 갖는 약제 함유 플라스터 |
AU59716/99A AU5971699A (en) | 1998-09-03 | 1999-08-28 | Plaster containing a medicament, with three functional layers |
JP2000568488A JP2002524414A (ja) | 1998-09-03 | 1999-08-28 | 3つの機能層を有する薬物硬膏剤 |
CA002341643A CA2341643A1 (en) | 1998-09-03 | 1999-08-28 | Plaster containing a medicament, with three functional layers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19840191A DE19840191A1 (de) | 1998-09-03 | 1998-09-03 | Arzneistoffhaltiges Pflaster mit drei funktionalen Schichten |
DE19840191.4 | 1998-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000013679A1 true WO2000013679A1 (de) | 2000-03-16 |
Family
ID=7879697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/006346 WO2000013679A1 (de) | 1998-09-03 | 1999-08-28 | Arzneistoffhaltiges pflaster mit drei funktionalen schichten |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1107742A1 (de) |
JP (1) | JP2002524414A (de) |
KR (1) | KR20010073008A (de) |
CN (1) | CN1320033A (de) |
AR (1) | AR024201A1 (de) |
AU (1) | AU5971699A (de) |
BR (1) | BR9913609A (de) |
CA (1) | CA2341643A1 (de) |
DE (1) | DE19840191A1 (de) |
WO (1) | WO2000013679A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100407406B1 (ko) * | 2001-10-06 | 2003-12-01 | 한웅코텍 주식회사 | 보형성이 있는 적층 시트 |
WO2004071499A1 (ja) * | 2003-02-12 | 2004-08-26 | Teika Pharmaceutical Co., Ltd. | ジクロフェナク含有貼付剤 |
DE102007006244B4 (de) | 2007-02-08 | 2012-03-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System zur Verabreichung wasserlöslicher Wirkstoffe |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2185187A (en) * | 1986-01-13 | 1987-07-15 | Alza Corp | Transdermal drug delivery device |
EP0569862A2 (de) * | 1992-05-12 | 1993-11-18 | Nitto Denko Corporation | Medizinische Selbstklebefolie und Arzneimittelzubereitung |
US5286490A (en) * | 1990-05-04 | 1994-02-15 | Colgate-Palmolive Company | Transdermal fluoride medication |
WO1997023206A1 (en) * | 1995-12-22 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Drug delivery device |
WO1998051288A1 (fr) * | 1997-05-12 | 1998-11-19 | Teikoku Seiyaku Co., Ltd. | Preparations de patch destinees a etre absorbees par voie percutanee |
WO1999039756A2 (de) * | 1998-02-06 | 1999-08-12 | Beiersdorf Ag | Trägermaterial für medizinische zwecke |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3409079A1 (de) * | 1984-03-13 | 1985-09-19 | Bayer Ag, 5090 Leverkusen | Medizinische pflaster |
JPS61293911A (ja) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
US4784653A (en) * | 1987-06-22 | 1988-11-15 | Johnson & Johnson Patient Care, Inc. | Absorbent adhesive dressing |
US5246705A (en) * | 1992-04-08 | 1993-09-21 | Cygnus Therapeutic System | Occlusive, elastomeric backing materials in transdermal drug delivery systems, and associated methods of manufacture and use |
-
1998
- 1998-09-03 DE DE19840191A patent/DE19840191A1/de not_active Ceased
-
1999
- 1999-08-28 BR BR9913609-0A patent/BR9913609A/pt not_active Application Discontinuation
- 1999-08-28 AU AU59716/99A patent/AU5971699A/en not_active Abandoned
- 1999-08-28 CA CA002341643A patent/CA2341643A1/en not_active Abandoned
- 1999-08-28 WO PCT/EP1999/006346 patent/WO2000013679A1/de not_active Application Discontinuation
- 1999-08-28 EP EP99968625A patent/EP1107742A1/de not_active Withdrawn
- 1999-08-28 KR KR1020017002469A patent/KR20010073008A/ko not_active Application Discontinuation
- 1999-08-28 CN CN99810580A patent/CN1320033A/zh active Pending
- 1999-08-28 JP JP2000568488A patent/JP2002524414A/ja active Pending
- 1999-09-03 AR ARP990104449A patent/AR024201A1/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2185187A (en) * | 1986-01-13 | 1987-07-15 | Alza Corp | Transdermal drug delivery device |
US5286490A (en) * | 1990-05-04 | 1994-02-15 | Colgate-Palmolive Company | Transdermal fluoride medication |
EP0569862A2 (de) * | 1992-05-12 | 1993-11-18 | Nitto Denko Corporation | Medizinische Selbstklebefolie und Arzneimittelzubereitung |
WO1997023206A1 (en) * | 1995-12-22 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Drug delivery device |
WO1998051288A1 (fr) * | 1997-05-12 | 1998-11-19 | Teikoku Seiyaku Co., Ltd. | Preparations de patch destinees a etre absorbees par voie percutanee |
EP0968710A1 (de) * | 1997-05-12 | 2000-01-05 | Teikoku Seiyaku Co., Ltd. | Pflaster-zubereitungen zur transdermalen absorption |
WO1999039756A2 (de) * | 1998-02-06 | 1999-08-12 | Beiersdorf Ag | Trägermaterial für medizinische zwecke |
Also Published As
Publication number | Publication date |
---|---|
CA2341643A1 (en) | 2000-03-16 |
KR20010073008A (ko) | 2001-07-31 |
AU5971699A (en) | 2000-03-27 |
AR024201A1 (es) | 2002-09-25 |
DE19840191A1 (de) | 2000-03-09 |
JP2002524414A (ja) | 2002-08-06 |
BR9913609A (pt) | 2001-10-09 |
EP1107742A1 (de) | 2001-06-20 |
CN1320033A (zh) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1009393B1 (de) | Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht | |
EP0720474B1 (de) | Lösemittelfrei herstellbares wirkstoffpflaster enthaltend flüchtige inhaltsstoffe | |
EP0261402B1 (de) | Transdermales therapeutisches System, seine Verwendung und Verfahren zu seiner Herstellung | |
EP0430019B1 (de) | Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil | |
EP1855660B2 (de) | Faserfreies transdermales therapeutisches system und verfahren zu seiner herstellung | |
EP0387694B1 (de) | Pflaster als therapeutisches System zur Verabreichung von Wirkstoffen an die Haut mit einer abgestuften Wirkstoffabgabe, Verfahren zu seiner Herstellung sowie Verwendung | |
EP0680325A1 (de) | Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil | |
DE3714140A1 (de) | Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut | |
DE102006026060B4 (de) | Transdermales Therapeutisches System enthaltend als Wirkstoff Nikotin und Verfahren zur Herstellung solcher Systeme | |
EP1231906B1 (de) | Transdermales therapeutisches system enthaltend leich flüchtige wirkstoffe | |
EP3119444B1 (de) | Überpflaster mit verbesserter verträglichkeit und einer langen haftungsdauer und verfahren zu seiner herstellung | |
WO1998029143A1 (de) | Extrem flexibles, dermal oder transdermal wirkendes pflaster und verfahren zu seiner herstellung | |
DE19642043A1 (de) | Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht | |
EP1107742A1 (de) | Arzneistoffhaltiges pflaster mit drei funktionalen schichten | |
EP1368008B1 (de) | Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol | |
EP0742716B1 (de) | Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid | |
DE3319469A1 (de) | System zur transdermalen applikation von pharmakotherapeutisch wirksamen substanzen | |
DE102018130469A1 (de) | Transdermales therapeutisches System mit Diffusionsbarriere | |
WO1994005295A1 (de) | Transdermales therapeutisches system mit pentylentetrazol als wirkstoff | |
DE102018118507A1 (de) | Transdermales therapeutisches System zur Abgabe von Scopolamin ohne Membran | |
DE102018216244A1 (de) | Transdermales therapeutisches System mit Barriereschicht | |
EP1147768A1 (de) | Transdermales therapeutisches System zur Abgabe von Dofetilid | |
DE10317108A1 (de) | Transdermal applizierbares Beruhigungs- und Sedierungsmittel | |
MXPA01002344A (en) | Plaster containing a medicament, with three functional layers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810580.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999968625 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2341643 Country of ref document: CA Ref document number: 2341643 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017002469 Country of ref document: KR Ref document number: 59716/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200101794 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/002344 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09786437 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999968625 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017002469 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017002469 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999968625 Country of ref document: EP |